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We have developed a miniviral vector, pH300, based on the human herpesviruses 1 and 4, herpes simplex
virus type 1 (HSV-1), and Epstein-Barr virus (EBV), carrying EBV sequences for plasmid episomal mainte-
nance and HSV-1 sequences for amplification and packaging in multimeric form into HSV-1 capsids in the
presence of a helper virus and helper cell line. A reporter gene, the bacterial lacZ gene, which expressed
b-galactosidase, was inserted into the multiple cloning site of pH300 to make pH300-lac. The packaged
pH300-lac DNA was very efficient in infecting human cells in tissue culture. The pH300-lac miniviral stock was
used to infect in vitro various human cell types derived from breast cancer, lung cancer, and liver cancer. Up
to 95% of cells were infected and expressed b-galactosidase activity after exposure to viral stock at a multi-
plicity of infection of 3. There was essentially no apparent cytotoxicity after infection of cultured cells in vitro.
To test in vivo gene delivery, human liver tumor cells preimplanted subcutaneously in nude mice and injected
in situ with pH300-lac showed high efficiency of ectopic gene expression. The pH300 miniviral vector is a simple
and effective gene transfer system which shows potential for gene therapy of cancer and inherited diseases.
Gene therapy has been considered a revolutionary method
for treating genetic diseases, cancer, and infectious diseases,
such as AIDS. The method of transfer of foreign genetic ma-
terial into cultured human cells and/or the human body will
play a fundamental role in the gene therapy practice. As cur-
rent vectors, such as retroviruses, adenoviruses, and vaccinia
viruses, are tested in clinical trials, their disadvantages and
limitations are becoming apparent (1, 12, 17, 19, 33). Manip-
ulation of an entire virus as a gene transfer vector generally
involves recombination of the gene of interest into the viral
genome. Such recombinant viruses are rather difficult to han-
dle, and their capacity for insertion of exogenous DNA is
relatively limited, from 7.5 kb (adenovirus) to 30 kb (herpes
simplex virus type 1 [HSV-1]). Although HSV-1 has a relatively
larger insert capacity, current vectors appear cytotoxic as a
result of residual viral proteins produced by the virus (11).
Helper virus-dependent miniviral vectors whose capacity for
insertion is theoretically as large as the size of the original viral
genome are being developed (31, 33). These vectors carry
cis-acting viral elements required for replication and packaging
into infectious virions. Since these vectors are defective for
viral production, they are dependent on a helper virus to pro-
vide the missing viral proteins in trans. A miniviral vector
combines the advantages of cloning the transgene in bacteria
and virus-mediated high efficiency of gene transfer. The theo-
retical capacity for large insertion into such a vector offers the
possibility to carry large DNA fragments including regulatory
genomic elements. Importantly, a miniviral vector can be de-
signed for the desired mode of action by assembling several
elements from different viruses, therefore creating a hybrid
miniviral vector system. Finally, a helper virus-free packaging
system similar to that of other viral vectors (5, 18, 23) could be
developed for an HSV-1 amplicon (7a).
The linear double-stranded DNA genome of HSV-1 is 152
kb in length and encodes at least 72 unique proteins (16). The
viral genome contains three origins of replication, one within
the unique long segment (oriL) and two within the repeats
flanking the unique short segment (oriS) (25, 27). An HSV-1
vector has a number of advantages as a gene delivery system.
These include a wide host range, the ability to infect nonrep-
licating cells like neurons in which the vectors can be main-
tained indefinitely in a latent state (26), and the ability to
prepare high-titer viral stocks. By using a plasmid containing
an HSV lytic origin of replication and HSV terminal packaging
signal sequences, Frenkel et al. (15, 24, 25, 32) demonstrated
that such an amplicon was amplified and packaged into infec-
tious HSV virions in the presence of a wild-type helper virus.
The virions contained multimeric forms of the original mono-
meric vector conforming to a rolling-circle replication mode.
Since the wild-type helper virus invariably caused cell death
due to lytic replication in infected cells, two replication-defec-
tive HSV systems have been developed as helper viruses. In a
helper virus temperature-sensitive system, the virion stocks
were produced at the permissive temperature (318C). Infection
of cells at 378C allowed miniviral vector delivery to the target
cell, whereas the temperature-sensitive mutant helper virus
was incapable of entering the lytic cycle and thereby cell death
was prevented (8, 9, 28). In another system, an essential im-
mediate-early gene 3 (IE3), encoding the ICP4 protein neces-
sary for early and late viral gene expression and virus replica-
tion, had been deleted from the helper viral genome. The
miniviral vector DNA was transfected into a helper cell line
which expressed a functional IE3 gene for complementation and
virion propagation was induced by infecting cells with the IE3
deletion mutant replication-incompetent helper virus (6, 9).
Epstein-Barr virus (EBV) is another member of the human
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herpesvirus family. EBV carries a unique latent replication
origin (oriP) which allows viral self-replication in human cells
without entering the lytic cycle (14, 21, 36). oriP-based vectors
allow episomal replication and maintenance in cells expressing
the EBV nuclear antigen EBNA-1, the only virus-encoded
transactivator of oriP (37). EBV-based miniviral vectors for
delivering large genes to human cells which can be stably
maintained in an episomal form in these cells have been de-
veloped (3, 29–31). In this study, we present a novel EBV/
HSV-based miniviral vector, pH300, allowing high-efficiency
lacZ gene transfer into various human cells in vitro and in vivo.
The vector contains the HSV lytic replication origin, oriS, and
an HSV packaging sequence, a, which allow vector replication
and packaging in the presence of the IE3 gene-deleted helper
virus in an IE3 gene-expressing helper E5 cell line. The latent
replication origin, oriP, and the transactivator, EBNA-1, from
EBV allow vector episomal maintenance in the E5 cells so that
viral stocks of high titers can be made. Effective b-galactosi-
dase expression in infected human cells, particularly in various
tumor-derived cell lines, is demonstrated. The efficiency of
infection can be as high as 95 to 99% in cultured human
fibroblast cells and epithelial cells without apparent cytotoxic-
ity. As an in vivo model for gene transfer, packaged pH300-lac
virions were injected into preimplanted human liver tumors in
nude mice. Histological 5-bromo-4-chloro-3-indolyl-b-D-galac-
topyranoside (X-Gal) staining showed lacZ gene expression in
many areas of the injected tumor. The pH300 miniviral vector
system should be a useful and efficient DNA delivery system
for gene expression studies and gene therapy experiments.
MATERIALS AND METHODS
Construction of pH300 and pH300-lac. pH300 is a 15.6-kb plasmid which was
constructed from a combination of several plasmids. The HSV replication origin,
oriS, is a BamHI fragment of pT011, kindly provided by N. Stow, Medical
Research Council, Glasgow, United Kingdom). The HSV packaging sequence, a,
is an EcoRI-HindIII fragment of pT011. The EBNA-1 gene and oriP of EBV,
and the Hygr gene, which codes for hygromycin B phosphotransferase, are from
a BamHI fragment of p500 (34). The backbone of the vector is pCDMV2A
(kindly provided by T. Tsukada, Kyoto University, Kyoto, Japan), which includes
a cytomegalovirus (CMV) promoter and simian virus 40 (SV40) poly(A) site,
elements required for bacteria growth, as an expression cassette consisting of a
ScaI-NruI fragment from pCDM8 (INVITROGEN); a multiple cloning site and
a 1.1-kb EcoRI-PstI stuffer fragment are derived from pCH110 (LKB, Pharma-
cia). pH300-lac was constructed by inserting a lacZ gene into the HindIII and
NotI sites of the multiple cloning site of pH300. The lacZ gene was a
HindIII-NotI fragment from pCDMV3-lac kindly provided by H. Takebe, Kyoto
University.
Cells and viruses. All cells were from the American Type Culture Collection
except where indicated. Cells were grown and maintained in Eagle’s minimal
essential medium (E-MEM; Gibco BRL) (or in RPMI 1640 where indicated)
containing 10% fetal bovine serum (HyClone), glutamine, and penicillin-strep-
tomycin and incubated at 378C in a humidified 5% CO2 incubator. E5 is a helper
cell line derived from African green monkey cells (Vero) and stably transfected
with an IE3 gene of HSV (6) (kindly provided by S. Bachenheimer, University of
North Carolina at Chapel Hill [UNC-CH]). The cells were maintained in 400 mg
of G-418 (Geneticin; GibcoBRL) per ml. NHF cells are fibroblasts derived from
normal skin (kindly provided by W. Kaufmann, UNC-CH). VA13 cells (Amer-
ican Type Culture Collection) were established from human WI38 cells by SV40
transformation. XP4BE cells are SV40-transformed skin fibroblasts derived from
a patient with xeroderma pigmentosum, group variant (an inherited DNA repair
defect). JML cells were established from tumor cells of a patient with Li-
Fraumeni syndrome. GM6914A cells are SV40-transformed skin fibroblasts de-
rived from a patient with Fanconi’s anemia. T98G cells are fibroblast-like human
glioma cells. SKBR-3, MCF-7, T47D, and DT-20 are all human breast carcinoma
cell lines. T47D and SKBR-3 cells were grown and maintained in RPMI 1640.
RD cells are spindle-shaped human rhabdomyosarcoma cells (kindly provided by
B. Weissman, UNC-CH). SW1271, A498, and HepG2 are human lung, kidney,
and liver carcinoma cell lines, respectively. The HSV-1 strain 171 IE3 deletion
mutant D30EBA (20) was kindly provided by P. Johnson, University of Califor-
nia, San Diego. The virus was grown and titers were determined in E5 cells.
Transfection and selection for hygromycin resistance. Transfection of pH300-
lac into E5 cells was carried out with Lipofectin as recommended by the man-
ufacturer (GIBCO BRL/Life Technologies, Gaithersburg, Md.). Optimal results
were obtained by using 2 mg of plasmid DNA and 10 mg of Lipofectin, each
diluted in 1 ml of Opti-MEM (GIBCO BRL/Life Technologies); the components
were mixed well and incubated at room temperature for 15 min. The liposome-
DNA complex was added to 53 105 actively growing E5 cells (washed previously
with Opti-MEM) in 2 ml of Opti-MEM in a six-well plate (Falcon, Lincoln Park,
N.J.). The Opti-MEM was replaced with complete medium after the cells were
incubated for 12 to 15 h at 378C in a humidified 5% CO2 incubator. Two days
after transfection, the cells were trypsinized and seeded into 10-cm-diameter
dishes at 106 per dish. The medium was replaced the following day by fresh
medium containing 200 mg of hygromycin B (ICN Biomedical, Inc., Aurora,
Ohio) per ml to select stable cell transformants.
Packaging and preparation of virion stocks. Hygromycin-resistant colonies
carrying the episomal pH300-lac were trypsinized, and 5 3 105 cells were plated
onto a 35-mm-diameter dish. At cell confluency, helper virus in 0.5 ml of Opti-
MEM was added to the dish at an MOI (multiplicity of infection) of 1. The
viruses were allowed to adsorb to the cells for 3 h at 378C in a humidified 5% CO2
incubator. Viral solutions were then aspirated, and 3 ml of E-MEM with 10% of
fetal bovine serum was added to the cells, which were kept for 3 days at 378C in
a humidified 5% CO2 incubator. The medium was collected and centrifuged at
1,000 3 g for 10 min, and the supernatant was used for virus titration and
infection. For production of helper virus, helper virus was used at an MOI of only
0.1.
Titration. (i) Helper virus. Viral stocks were diluted in 100 ml of Opti-MEM,
and 1023 to 1028 dilutions were used to infect confluent monolayers of E5 cells
grown in 24-well plates. The viruses were allowed to adsorb to the cells for 3 h
at 378C in a humidified 5% CO2 incubator. The virus solutions were aspirated
and overlaid with 1 ml of E-MEM containing 5% fetal bovine serum and 1%
low-melting-point agarose which was previously equilibrated to 428C. The low-
melting-point agarose medium was allowed to solidify at room temperature and
then placed at 378C in a humidified 5% CO2 incubator for 3 days. Plaques were
then visualized by staining with 0.5 ml of 0.6% crystal violet in 50% ethanol for
5 min. The plates were dried, and plaques were counted. Titers of helper virus
were expressed as PFU per milliliter.
(ii) Minivirus. pH300-lac miniviral vector stocks were titered by infection of
T98G cells as described above. Assuming that one X-Gal-positive T98G cell
represented one infectious pH300-lac virion, the titers were expressed as blue
cell-forming units per milliliter.
In vitro and In vivo infection with pH300-lac. For in vitro infection, cultured
human cells from different sources, including a number of tumor cell lines (see
Table 2), were trypsinized, counted, and seeded at appropriate cell densities.
When cells reached confluency, they were infected by defective viral pH300-lac
at an MOI of 3 for 3 h. For in vivo studies, female nude mice (Harlan Labora-
tories) were injected subcutaneously at two symmetrically located sites with 107
HepG2 cells suspended in 0.1 ml of phosphate-buffered saline (PBS). When
visible tumors approximately 0.5 cm3 in size developed 1 month later, miniviral
pH300-lac was administered to the tumor at one site by a multidirection injection
in situ with 0.2 ml of viral solution, approximately 23 106 PFU. As a control, the
tumor on the other side of the mouse was injected with 0.2 ml of PBS. The
b-galactosidase activity was measured 24 h later for both in vitro and in vivo
infection as described below.
Assays for b-galactosidase activity. Two assays were used to detect b-galac-
tosidase activity in pH300-lac infected cells. For visualization of virions carrying
the lacZ gene, infected cells were rinsed with PBS on day 2 following infection.
The cells were then fixed for 5 min at room temperature in 2% formaldehyde–
0.3% glutaraldehyde in PBS and stained by incubation in a chromophore solu-
tion containing 0.1% X-Gal (Promega), 5 mM K4Fe(CN)6 z 3H2O, 5 mM
K3Fe(CN)6, and 2 mM MgCl2 in PBS. Incubation continued at 378C until color
developed (usually within 30 to 60 min). For quantitative measurement of b-ga-
lactosidase activity, all cells were trypsinized after 48 h of infection and washed
once in PBS solution. Then 106 cells were resuspended in an o-nitrophenyl-b-
D-galactopyranoside (ONPG) lysis solution (0.45 mM ONPG and 0.5% Nonidet
P-40 in Hanks balanced salt solution) and incubated at 378C in a 5% CO2
humidified incubator, and the optical density at 420 nm was read 1 h later.
Expression of b-galactosidase activity in tumor tissue was detected as described
previously (4). Briefly, freshly isolated tissue was flash-frozen in isopentane and
cooled in liquid nitrogen for the preparation of cryosections. These cryosections
(;8 to 10 mm) were fixed briefly with glutaraldehyde and histochemically stained
as described for cell monolayers but incubated for 4 to 16 h.
UV irradiation of virus. Stocks of packaged pH300-lac were irradiated with
UVC light (254 nm) at various dosages. The effect of UV irradiation on lacZ
gene expression of pH300-lac, i.e., the b-galactosidase activity, was determined
by infection of T98G cells at an MOI of 3. X-Gal staining and measurement of
ONPG expression levels were both carried out 24 h later.
Slot blot and DNA hybridization. DNA from packaged pH300-lac and helper
virus (D30EBA) was prepared and transferred to a nylon membrane (Magna-
graph Nylon; MSI) for slot blot hybridization analysis (2). One million copies of
pH300-lac and pGH83, the plasmid carrying the HSV IE110 promoter (kindly
provided by S. Bachenheimer), were also loaded as copy number standards.
Membranes were hybridized with pH300-lac miniviral vector-specific (hygromy-
cin, BglII-EcoRI fragment, 1,068 bp) and HSV helper virus-specific (IE110 pro-
moter, HindIII-BamHI fragment, 950 bp) probes. The radioactive signals were
exposed and analyzed on a PhosphorImager (Molecular Dynamics). The data
were corrected by the fact that the packaged multimeric pH300-lac virions
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contained about eight copies of pH300-lac plasmid whereas the helper virus
contained only two copies of the HSV IE110 promoter.
RESULTS
Strategy for the generation of the hybrid EBV/HSV-1 pH300
and pH300-lac miniviral vectors. The 15.6-kb mini-HSV-1 vec-
tor, pH300, is schematically shown in Fig. 1A. pH300 contains
the HSV-1 sequences oriS (HSV-1 origin of DNA replication)
and a (viral packaging). oriP and EBNA-1 of EBV allow epi-
somal maintenance of pH300 in human cells under hygromycin
B selection. The SV40 origin has a bidirectional promoter
function, with the early and late promoters driving the Hygr
and EBNA-1 genes, respectively. The expression cassette con-
sists of a CMV immediate-early promoter and the SV40 early
region poly(A) sequence for termination of transcription to
drive transgene expression. In addition, a multiple cloning site
and a stuffer fragment are included for easy subcloning. The
miniviral reporter vector pH300-lac (Fig. 1B) is essentially the
same as pH300 except for the insertion of the lacZ gene be-
tween the HindIII and NotI sites of pH300.
Production of packaged pH300-lac HSV-1 miniviral virions.
pH300-lac was transfected into cultured E5 cells and subjected
to selection with hygromycin B. After 2 to 3 weeks, stable
resistant colonies were replated and infected with the helper
virus D30EBA. The virion stocks consisted of a mixed popu-
lation of miniviral pH300-lac and helper D30EBA. Titers of
the produced stocks and ratios of pH300-lac to D30EBA are
presented in Table 1. The packaging efficiency of pH300-lac
was very reproducible in different preparations, ranging be-
tween 2.5 3 106 and 5 3 106 blue cell-forming units/ml. The
production of helper virus, however, varied between different
stocks, resulting in ratios of packaged pH300-lac to D30EBA
ranging from 15 to 0.256. When a pH300-lac viral stock was
prepared after transient transfection of pH300-lac into E5 cells
without hygromycin selection and after infection with helper
virus, less pH300-lac DNA was packaged and the ratio of
pH300-lac to helper virus was only 0.04. Such a low ratio is
similar to those observed by others by others with HSV am-
plicon vectors (13). To confirm the packaging of pH300-lac,
slot blot hybridization was performed (Fig. 2). This analysis
showed that the ratios of pH300-lac to D30EBA viral particles
were in the range of 1.98 to 0.165.
Effective gene delivery by infectious pH300-lac into various
human cell types. Cultured normal and genetically defective
human cells as well as a number of tumor cells from various
tissues (Table 2) were infected with miniviral pH300-lac, and
b-galactosidase activity was evaluated by X-Gal staining. As
illustrated in Fig. 3, NHF cells, normal primary human fibro-
blasts which are resistant to standard transfection methods,
were very efficiently infected (Fig. 3A), as was JML, a tumor
cell line derived from a patient with Li-Fraumeni syndrome
(Fig. 3B). XP4BE and GM6914A, SV40-transformed human
fibroblast lines derived from patients with the DNA repair
defect xeroderma pigmentosum variant and Fanconi’s anemia,
FIG. 1. Structures of pH300 and pH300-lac mini-EBV/HSV-1 vectors.
pH300 and pH300-lac have the same structure. pH300 has a multiple cloning site
and a stuffer fragment for multipurpose insertion and cloning. pH300-lac con-
tains a constitutively expressed lacZ gene inserted at the HindIII and NotI sites
of pH300. Ori S, HSV-1 origin of DNA replication. “a,” HSV packaging se-
quence; Ori P, EBV origin of DNA replication; SV40 Ori, SV40 origin of DNA
replication; CMV, CMV immediate-early promoter; poly A, SV40 early region
poly(A) sequence for termination of transcription; Ampr, ampicillin resistance
gene; Col E1 ori, pBR322 replication origin.
TABLE 1. Efficiency of packaging pH300-lac DNA into
HSV-1 particles
Viral stocka pH300-lac titerb D30EBA titerc Ratiod
1 3.0 3 106 2.0 3 105 15
2 2.3 3 106 2.0 3 106 1.15
3 2.56 3 106 1.0 3 107 0.256
4 2.56 3 106 8.0 3 106 0.32
5 1.3 3 106 3.0 3 106 0.433
6 4.3 3 106 2.2 3 106 1.95
7 4.1 3 106 1.3 3 107 0.35
8 4.0 3 104 1.0 3 106 0.04
9 2 3 106
10 4 3 106
11 3.5 3 106
a Viral stocks consist of a mixed population of pH300-lac and helper virus
D30EBA (1 to 8) or helper virus only (9 to 11). Viral stocks 1 to 7 were produced
after pH300-lac transfection into E5 cells and selection with hygromycin; viral
stock 8 was produced immediately after transfection without hygromycin selec-
tion; viral stocks 9 to 11 were produced from original E5 cells.
b Titers of pH300-lac miniviral vector stocks were determined by infection of
T98G cells as blue cell-forming units per milliliter.
c D30EBA (helper virus) titers were determined in E5 cells as PFU per
milliliter.
d Ratios were obtained by dividing pH300-lac titer by D30EBA titer.
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respectively, were also infected efficiently (Fig. 3C and D). In
contrast, maximum transfection efficiencies of 10 to 20% were
obtained by lipofection in these cell lines (data not shown).
The highest efficiency was obtained with T98G glioblastoma
cells (Fig. 3E and F). Figure 4 illustrates the infectivity of
pH300-lac on tumor cells derived from different tissues. Tumor
cells from breast (T47D, SKBR-3, MCF-7, and DT-20), lung
(SW1271), and liver (HepG2) carcinomas were efficiently in-
fected at an MOI of 3 (Fig. 4), while cells from muscle (RD)
and kidney (A498) tumors were less efficiently infected (not
shown). The results are summarized in Table 2. Most of the
cells were efficiently infected in vitro by pH300-lac at an MOI
of 3. Therefore, the pH300 miniviral vector can deliver and
express transgenes such as lacZ with high efficiency in various
human cell types.
To demonstrate de novo expression from the mini-EBV/
HSV-1 virus, pH300-lac virions were irradiated with various
doses of UVC (254 nm) and then used to infect T98G cells.
X-Gal staining 24 h after infection showed that the number of
X-Gal-positive cells was decreased in response to the UVC
doses (data not shown). ONPG measurements taken 1 week
after infection showed decreasing lacZ expression with increas-
ing UVC doses (Fig. 5). The dose of UVC irradiation needed
to reduce lacZ expression to 37% (1 lethal hit) was approxi-
mately 160 J/M2. About 1 to 2% X-Gal staining in T98G cells
was observed at 4 weeks following infection at an MOI of 3.
ONPG measurements of pH300-lac-transduced T98G cells at
this MOI showed a peak of lacZ gene expression 3 days postin-
fection, with a continuous decline of ONPG levels thereafter.
ONPG levels above that of uninfected controls were obtained
up to 5 weeks following infection (data not shown). In these
experiments, the transduced cells were cultured in the absence
of selection and split at a ratio of 1:4 when confluent. The
packaged pH300-lacZ expressed the lacZ gene after infection
of target cells. Trypan blue staining did not reveal any apparent
cytotoxicity in infected cells, even at an MOI of 3. Hence, such
infected cells could be easily grown in large quantities for
further analysis.
Functional gene delivery in vivo by pH300-lacZ virus into
human tumor cells. Infection and expression of pH300-lac in
vivo were evaluated in animals (female nude mice from Harlan
Laboratories) by in situ injection of pH300-lac virions into
HepG2 tumors that were preimplanted by subcutaneous injec-
tion (Fig. 6). In vivo infection and expression of pH300-lac was
demonstrated by X-Gal staining 24 h after injection of the virus
into the tumor tissue. Cells prepared from freshly isolated
tumor tissue stained blue, indicating that the lacZ gene was
delivered to and expressed b-galactosidase in these tumor
cells. Among the randomly prepared cryosections, 25% fully
expressed lacZ, with all areas showing blue staining (Fig. 6A
and B); 38% exhibited partial expression, with most areas
showing blue staining (Fig. 6C and D); 15% exhibited less
expression (Fig. 6E and F), and about 22% of the cryosections
showed only scattered blue staining. In contrast, in cryosec-
tions prepared from mock-injected control tissue on the same
animal, blue staining was not detectable (Fig. 6G and H).
DISCUSSION
An infectious hybrid EBV/HSV-based miniviral vector,
pH300, was constructed and used to deliver a reporter gene,
lacZ, into human cells both in vitro and in vivo. pH300 is
capable of high efficient gene transfer and expression in a
variety of human cells, both in vitro and in vivo. It also carries
FIG. 2. Slot blot DNA hybridization analysis of the ratio of pH300-lac and
helper virus (D30EBA) particles in viral stocks. The pH300-lac-specific probe
was a 1.07-kb BglII-EcoRI Hygr fragment. The HSV helper-specific probe was
the 0.95-kb IE110 promoter HindIII-BamHI fragment. The radioactive signals
were exposed and analyzed on a PhosphorImager (Molecular Dynamics). The
ratios were corrected for copy numbers of the probes Hygr and IE110 promoter
in the packaged multimeric pH300-lac and monomeric HSV-1, respectively.
TABLE 2. Infection and expression of pH300-lac in human cells
Cell line Tissue source Morphology Pathology % X-Gal-positive cellsa
NHF Skin Fibroblast Normal 90–95
VA13 Lung Epithelial-like SV40 transformed $95
JML Skin Fibroblast Li-Fraumeni syndrome 90–95
XP4BE Skin Fibroblast DNA repair defect $95
GM6914A Skin Fibroblast Fanconi’s anemia 80–90
T98G Nerve Fibroblast Glioblastoma $95
T47D Breast Epithelial Carcinoma $95
SKBR-3 Breast Epithelial Carcinoma $95
MCF-7 Breast Epithelial Carcinoma 80–90
DT-20 Breast Epithelial Carcinoma $95
RD Embryonal Spindle-like Rhabdomyosarcoma 50–55
SW1271 Lung Epithelial Carcinoma 80–90
A498 Kidney Epithelial Carcinoma 50–60
HepG2 Liver Epithelial Carcinoma $95
a Cells were infected with pH300-lac at an MOI of 3, and X-Gal staining was carried out 24 h later. Fractions of X-Gal-positive cells were evaluated in at least two
independent experiments.
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a bacterial plasmid backbone for easy manipulation and am-
plification in prokaryotic cells.
Latent episomes as a strategy for efficient packaging. One
notable characteristic of pH300 is that it contains the latent
EBV replication origin, oriP, and its transactivator, EBNA-1.
These two elements make the pH300 vector capable of self-
replication and mitotic segregation in an episomal form in
dividing human cells (22, 29, 35, 36). Episomal maintenance of
the vector is an essential step for effective vector replication
and packaging into HSV capsids in the presence of HSV-1
helper virus. In addition, the Hygr gene ensures that every
helper cell contains the miniviral vector and that high titers of
viral stock can be made. Under hygromycin selection, helper
cells maintained episomal pH300-lac very stably, and pH300-
lac virions could be produced from the helper cells for at least
6 months in culture (unpublished observations). By contrast,
the HSV-1 amplicon could not be episomally maintained in
helper cells for extended periods of time, and viral stocks had
to be produced immediately after transfection (8, 10, 15, 24, 25,
28, 32). Because of low transfection efficiency, only a fraction
of cells in the transiently transfected population contained the
amplicon. Since the ratio of amplicon to helper virus was very
low in the initial passage, higher ratios of viral stocks could be
obtained only by successive propagation at a higher MOI for at
FIG. 3. X-Gal staining of human cells infected in vitro with pH300-lac virions. Cells were infected at an MOI of 3 for 3 h and stained with X-Gal 24 h later. (A)
NHF (normal fibroblasts), magnification, 360; (B) JML (Li-Fraumeni syndrome), magnification, 360; (C) XP4BE (xeroderma pigmentosum variant), magnification,
363; (D) GM6914A (Fanconi’s anemia), magnification 395; (E and F) T98G (glioblastoma), magnifications, 395 and 3304, respectively.
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least five to eight passages (8, 13, 24). However, what limits the
use of this strategy is the apparent difficulty of reproducing
such a high ratio of amplicon to helper virus (7). In accordance
with these results, the ratio of miniviral pH300-lac vector to
helper virus after a single passage of viral stock propagated in
helper cells without hygromycin selection was only about 4%
(Table 1). In contrast, slot blot hybridization analysis showed
that the pH300-lac/D30EBA ratios were in the range of 1.98 to
0.165 (Fig. 2), while biological titration indicated ratios of
packaged pH300-lac to D30EBA varying between 15 and 0.256
(Table 1). A lower ratio of pH300-lac to helper by biological
titration than by molecular hybridization analysis may be due
to the fact that the lysis plaque assay requires multiple rounds
of viral cycles in E5 cells, while the lacZ-based assay relies on
a single infection cycle. Titers of pH300-lac virions, however,
are reproducible because expression of the lacZ gene is more
direct than viral titration based on lysis plaques.
Hybrid mini-EBV/HSV-1 for reduced helper interference.
The pH300-lac is defective for viral production for both EBV
and HSV-1 and is thus dependent on a helper virus to provide
all needed viral proteins in trans. The helper HSV-1
(D30EBA) used for pH300-lac production is also replication
defective and incapable of lytic infection as a result of a dele-
tion in both copies of the IE 3 gene. Viral functions of IE3 are
FIG. 4. X-Gal staining of human tumor cell lines infected with mini pH300-lac virions. Cells were infected at an MOI of 3 for 3 h and stained with X-Gal 24 h later.
(A) T47D (breast cancer), magnification, 360; (B) SKBR-3 (breast cancer), magnification, 360; (C) MCF-7 (breast cancer), magnification, 3190; (D) DT-20 (breast
cancer), magnification, 3190; (E) SW1271 (lung cancer), magnification, 360; (F) HepG2 (liver cancer), magnification, 360.
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essential for early gene expression, viral DNA replication, late
gene expression, and thus the production of progeny virus (6).
Consequently, the helper virus can be replicated and propa-
gated only through the lytic cycle in helper cells such as E5
expressing the IE3 gene through complementation. Human
cells do not contain a homologous IE3 gene and are therefore
not permissive for HSV helper virus replication. However, the
regeneration of wild-type HSV-1 through recombination be-
tween the helper viral genome and the chromosomally inte-
grated complementing viral genes during in vitro passage has
been reported (11). In contrast, we have not been able to
detect any rescued wild-type virus in our experiments (data not
shown). Such observation may be due to a combination of the
low frequency of such recombination events (1026 to 1027 in
reference 11) and the usage of a single short-term infection
cycles at low MOI of helper for making viral stocks (instead of
multiple repetitive passages at high MOI of helper). As addi-
tional safety precautions, several strategies can be envisioned
to reduce the probability of recombination in vitro or in vivo,
such as the engineering of a cell line expressing multiple viral
genes codeleted from a helper virus (10a) or the development
of complementing viral subgenomes to passage a fragmented
helper virus (7a). Our observations indicate that there were no
apparent cytopathic effects after infection of human cells with
pH300-lac virions in vitro. In a recent study, Johnson et al. (11)
detected cytotoxicity in cells infected with a replication-defec-
tive mutant (IE3 deletion) of HSV-1, CgalD3. In confirmation,
the helper virus only (D30EBA) caused cell death 3 days after
infection (unpublished observations). The miniviral system
pH300 also carries helper virus in viral stocks. Specifically, the
pH300-lac viral stocks consisted of an average vector/helper
ratio of 0.74 (Table 1, viral stocks 2 to 7), with the noticeable
exception of a ratio of 15.0 for viral stock 1. In contrast, a ratio
of 0.04 was observed when the traditional method of transient
transfection of the amplicon was used (viral stock 8). Hence,
the presence of helper in the pH300 system was reduced by ca.
18-fold (0.74/0.04). Such a lower amount of helper virus should
help reduce the cytopathic effects observed after infection with
HSV-1 recombinants or previous HSV amplicons. In addition,
the lower amount of helper virus could also diminish potential
immune reactions to viral components in vivo. However, the
usage of helper HSV to generate pH300 viral stocks still pre-
sents the disadvantage of some helper contamination, which
could preserve some virus-induced in vivo cytotoxicity. Such a
potential cytotoxicity of HSV is a major concern, which could
be reduced if not completely eliminated through the develop-
ment of helper virus-free packaging systems for HSV vectors.
Multimeric packaging for efficient gene expression. The
EBV/HSV-1 hybrid vector pH300 is capable of infecting a
variety of types of human cells, both in vitro and in vivo (Fig.
3 to 5). The b-galactosidase activity detected after infection of
pH300-lac may not necessarily derive from de novo expression
of the transduced lacZ gene, since the b-galactosidase protein
may be encapsidated into helper and/or defective virions dur-
ing the packaging process. To exclude such a possibility, we
examined the effect of UVC irradiation on b-galactosidase
activity after infection. As shown in Fig. 6, b-galactosidase
activity of miniviral pH300-lac was inhibited by UV irradiation
in proportion to the dose (Fig. 6), demonstrating that b-galac-
tosidase activity of the lacZ gene was indeed conferred by the
transduced pH300-lac DNA and due to de novo expression.
Because the pH300-lac DNA is packaged into HSV particles,
its tropism of infection is probably as wide as that of the
wild-type HSV-1. We have also successfully infected primary
mouse liver cells with pH300-lac and achieved about 95%
X-Gal-stained cells (34a). Such a result indicates a host range
wider than human cells. However, episomal replication of the
vector is not expected to occur in rodent cells since the oriP/
EBNA-1 replication system from EBV is limited essentially to
human and primate cells. For certain types of human cells such
as RD and A498, derived from muscle and kidney, respec-
tively, infection efficiency was somewhat reduced. This could
be due to a lower number of HSV-1 receptors on the mem-
branes of those cells. Alternatively, such cell types may not
sustain efficient expression from the CMV immediate-early
promoter. Our data indicated that lacZ gene expression gen-
erally lasted for approximately 2 weeks in the majority of
human cell lines tested. In T98G cells, b-galactosidase activity
could be detected for up to 5 weeks after in vitro infection
(data not shown). Such a decrease of b-galactosidase activity as
a function of time in infected cells might also be due to pro-
moter inactivation or, alternatively, to vector loss in the ac-
tively growing cells. The very intense staining of cells infected
both in vitro and in vivo indicates that the CMV promoter was
very active. Because of the smaller size of the pH300-lac and its
lytic replication via a rolling circle, a mini-HSV-1 vector is
packaged as linear multimeric concatemers consisting of iden-
tical head-to-tail repeat units (24). Hence, the number of mul-
timers in a virion is dictated by the size ratio of the monomeric
vector to the overall 152 kb of HSV-1 DNA (33). Such a
multimeric structure may also contribute to high expression
levels per cell. By using pulsed-field gel electrophoresis and
Southern blot methods, Sun and Vos (31) measured a pack-
aging size range of 150 to 200 kb for a multimeric mini-EBV,
another member of the human herpesvirus family. Hence, the
pH300-lac vector is expected to be packaged as 8-mers into
HSV-1 viral particles. The maximum size of insert DNA that
can be packaged into mini-HSV-1 viral capsids is not known.
Theoretically, insertion of nonviral sequences into mini-HSV-1
as a monomeric vector may reach the total size of the viral
genome. In the case of pH300, the theoretical maximum in-
sertion size of foreign DNA might be as large as 130 to 140 kb.
Effective in vivo delivery in tumors as a potential tool for
gene therapy. Successful infection of tumor cells in vivo (Fig. 5)
by in situ injection of pH300-lac virions indicates that the
miniviral pH300 has potential use for human tumor treatment
FIG. 5. Effect of UVC on infection and expression of pH300-lac in cultured
human glioblastoma T98G cells. The viral stock was irradiated with various doses
of UVC as indicated and then used to infect T98G cells. The b-galactosidase
activity of miniviral pH300-lac was determined 1 week later by the measurement
of optical density (OD) at 420 nm. Each bar represents the mean value of three
independent determinations of ONPG.
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FIG. 6. Histological detection of b-galactosidase activity in nude mouse tumors 24 h after pH300-lac injection into human tumor cells grown in nude mice. (A and
B) Area with high lacZ expression; (C and D) area with medium lacZ expression; (E and F) area with less lacZ expression; (G and H) control area. Magnifications:
A, C, E, and G, 319; B, D, F, and H, 3190.
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in vivo. The observed strong and transient expression of an
inserted gene in pH300 may be sufficient in killing tumor cells.
Alternatively, the mini-HSV-1 vector could be used in the
central nervous system for treating acquired and hereditary
diseases due to the neurotropism of HSV-1. Geller and
Breakefield (8) explored the feasibility of the mini-HSV-1 am-
plicon to transfer expressed genes into nervous cells. A fol-
low-up study by Kaplitt et al. (13) also using the lacZ gene on
an HSV-1 amplicon confirmed mini-HSV-1 as a promising
viral vector for gene transfer and expression in the central
nervous system of the adult rat brain in vivo. Preexisting or
future HSV infection could theoretically induce vector reacti-
vation and its spread to other parts of the human body. This
issue is a primary concern for future gene therapy protocols
based on any infectious vector derived from endemic human
viruses. Such potential pathogenesis induced by rescued infec-
tious HSV vector spreading at new sites would not be expected
to be as severe as that of wild-type virus infection, since all
herpesvirus genes have been deleted from the vector. None-
theless, strategies such as controlled tissue-specific gene ex-
pression and inclusion of suicide genes for viral destruction will
have to be considered as safety barriers. In summary, the wide
tropism of infection, the simplicity of handling, the potentially
large capacity of DNA insertion, the undetectable cytotoxicity
in vitro, and the high efficiency of infection and expression in
vivo may render the EBV/HSV-1 hybrid vector pH300 a po-
tentially excellent gene transfer system for future gene therapy
applications.
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